Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Microbiology

Open Access

Induction of a chemoattractant transcriptional response by a Campylobacter jejuniboiled cell extract in colonocytes

  • Kenneth H Mellits1Email author,
  • Ian F Connerton1,
  • Michael F Loughlin1,
  • Peter Clarke2,
  • Julie Smith3,
  • Eleanor Dillon1,
  • Phillippa L Connerton1,
  • Francis Mulholland4 and
  • Christopher J Hawkey3
BMC Microbiology20099:28

https://doi.org/10.1186/1471-2180-9-28

Received: 26 June 2008

Accepted: 04 February 2009

Published: 04 February 2009

Abstract

Background

Campylobacter jejuni, the commonest cause of bacterial diarrhoea worldwide, can also induce colonic inflammation. To understand how a previously identified heat stable component contributes to pro-inflammatory responses we used microarray and real-time quantitative PCR to investigate the transcriptional response to a boiled cell extract of Campylobacter jejuni NCTC 11168.

Results

RNA was extracted from the human colonocyte line HCA-7 (clone 29) after incubation for 6 hours with Campylobacter jejuni boiled cell extract and was used to probe the Affymetrix Human Genome U133A array. Genes differentially affected by Campylobacter jejuni boiled cell extract were identified using the Significance Score algorithm of the Bioconductor software suite and further analyzed using the Ingenuity Pathway Analysis program. The chemokines CCL20, CXCL3, CXCL2, Interleukin 8, CXCL1 and CXCL6 comprised 6 of the 10 most highly up-regulated genes, all with Significance Scores ≥ 10. Members of the Tumor Necrosis Factor α/Nuclear Factor-κB super-family were also significantly up-regulated and involved in the most significantly regulated signalling pathways (Death receptor, Interleukin 6, Interleukin 10, Toll like receptor, Peroxisome Proliferator Activated Receptor-γ and apoptosis). Ingenuity Pathway Analysis also identified the most affected functional gene networks such as cell movement, gene expression and cell death. In contrast, down-regulated genes were predominantly concerned with structural and metabolic functions.

Conclusion

A boiled cell extract of Campylobacter jejuni has components that can directly switch the phenotype of colonic epithelial cells from one of resting metabolism to a pro-inflammatory one, particularly characterized by increased expression of genes for leukocyte chemoattractant molecules.

Background

Campylobacter jejuni (C. jejuni) is a gram-negative micro-aerophilic bacterium responsible for the majority of human bacterial enteric infections worldwide [1, 2]. C. jejuni is commonly found as a commensal organism in the intestinal tracts of a wide range of wild and domestic animals, including commercial poultry [3]. Cross-contamination from raw poultry or insufficient cooking of poultry meat are common sources of infection. Enteric infections by this pathogen are often associated with a potent localized inflammatory response. Symptoms arising from infection include watery or bloody diarrhoea with abdominal cramping and fever. In addition, C. jejuni can be invasive and is associated with septicaemia, meningitis, Guillain-Barré syndrome [4] and more recently with immuno-proliferative disease [5].

C. jejuni virulence factors for human disease include flagella based chemotaxis, adhesin-based cellular adherence, host cell invasion and the elaboration of a heat labile cytolethal distending toxin (CLDT) [2, 6, 7] In previous studies we have additionally shown that a heat stable C. jejuni boiled cell extract (BCE) is able to activate the transcription factor NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) [8]. This signalling molecule is responsible for inducing the expression of a number of genes involved in inflammation and cell mediated immunity [9], including chemokines capable of attracting leukocytes, resulting in inflammation. NF-κB is held inactive in the cytoplasm of a cell, whilst its nuclear localization domain is masked by inhibitory IκB proteins. If IκB is phosphorylated, leading to ubiquitin-mediated proteolysis, then NF-κB is released to transport to the nucleus of the cell, where it affects transcription of κB-responsive promoters. Therefore products that activate NF-κB can be presumed to have a strong role in triggering inflammation. Previous work has shown that live C. jejuni and a BCE can induce both NF-κB, and the synthesis and release of the chemokine interleukin-8 [8].

In order to identify a wider range of genes affected by C. jejuni products and assess the relative importance of the NF-κB response we used microarray technologies to identify genes that were both up and down-regulated in HCA-7 cells after exposure to a C. jejuni BCE [8, 10]. Use of the Ingenuity Pathway Analysis (IPA) program suite enabled us to group co-regulated genes in order to identify the cellular signalling pathways activated in HCA-7 cells in response to C. jejuni BCE. The transcriptomic data were confirmed by real time quantitative PCR (RQ-PCR).

Methods

C. jejuniculture and preparation of BCE

The type strain C. jejuni National Collection of Type Cultures (NCTC) 11168 was used throughout these experiments, since it was originally isolated from a patient with diarrhoea, its genome sequence is available and it has a well-characterized pathological phenotype [11]. It was incubated on blood-agar plates (Blood Agar Base CM0271 from Oxoid, Basingstoke, UK with 5%, v/v defibrinated horse blood) under micro-aerobic conditions for 24 h. and used to inoculate Nutrient Broth no. 2 (Oxoid CM0067, 600 ml in 1000 ml flask). Inoculated flasks were shaken at 140 rpm at 42°C for 16 h. under micro-aerobic conditions. Culture purity was determined by plating samples from each overnight culture onto blood plates and incubating for 24 h., 42°C in micro-aerobic conditions. Bacteria were collected by centrifugation at 10,000 g for 15 min. The cell pellet was washed three times in Phosphate Buffered Saline (PBS), weighed and re-suspended in PBS to achieve a 10% (w/v) suspension, which was boiled for 10 min., cooled on ice for 5 min. before being centrifuged at 10, 000 g for 10 min. The supernatant was collected, passed through a 0.2 μm filter to remove residual bacteria and stored at -20°C until required.

HCA-7 cell culture and treatment with C. jejuniBCE

The human colonocyte line HCA-7 [10], clone 29, was grown to confluence in a 5% CO2 atmosphere in monolayer cultures on monolayer dishes in Dulbecco's Modified Eagle's Medium supplemented (DMEM) with 100 μg/ml penicillin, 100 μg/ml streptomycin and fetal calf serum at 10% (v/v, Fisher Scientific, Loughborough, UK) at 37°C. Twenty-four hours prior to induction by BCE, HCA-7 cells were transferred to serum-free DMEM. HCA-7 cells were then incubated for 6 h. with 25 μl BCE or PBS control in a total volume of 1 ml of DMEM. The BCE preparation was determined in parallel to induce NF-κB 300-fold using a reporter cell assay [8]. At 6 h. post induction total RNAs were extracted using RNAeasy columns (Qiagen, West Sussex, UK). Total RNA yields and purity were determined using an Agilent 2100 Bioanalyzer (Agilent Technologies UK Limited, Stockport, UK).

cDNA synthesis

Approximately 10 μg of total RNA was reverse transcribed at 42°C for 1 h. to generate first strand DNA using 100 pmol oligo dT(24) primer containing a 5'-T7 RNA polymerase promoter sequence (5'-GCCAGTGAATTGTAATACGACTCACTATAGGGAGGCGG-(dT)24-3'), 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2, 10 mM dithiothreitol (DTT), 10 mM dNTPs and 200 units SuperScript II reverse transcriptase (Invitrogen Life Technologies, Strathclyde, UK). Second strand DNA synthesis was carried out at 16°C for 2 h., using 10 units of E. coli polymerase I, 10 units of E. coli DNA ligase and 2 units of RNase H in a reaction containing 25 mM Tris-HCl (pH 7.5), 100 mM KCl, 5 mM MgCl2, 10 mM (NH4)SO4, 0.15 mM β-NAD+ and 10 mM dNTPs. 10 units of T4 DNA polymerase were added and the reaction allowed to proceed for a further 5 min. before termination with 0.5 M EDTA. Double stranded cDNA products were purified using the GeneChip Sample Cleanup Module (Affymetrix, Santa Clara, CA, USA).

cRNA synthesis

The synthetic cDNAs were in vitro transcribed using T7 RNA polymerase (ENZO BioArray High Yield RNA Transcript Labeling Kit, Affymetrix, Santa Clara, CA, USA) with biotinylated ribonucleotides to generated biotinylated complementary RNAs (cRNAs). The cRNAs were purified using the GeneChip Sample Cleanup Module before random fragmentation at 94°C for 35 min. in a buffer containing 40 mM Tris-acetate (pH 8.1), 100 mM potassium acetate and 30 mM magnesium acetate to generate molecules of approximately 35 to 200 bases long.

Array hybridization

Changes in gene transcription were analyzed by hybridization to Affymetrix Human Genome U133A array (HG-U133A) which contains probes for over 22,000 transcripts, including representation of the RefSeq database sequences and probe sets http://www.affymetrix.com/products_services/arrays/specific/hgu133.affx. The fragmented cRNAs were mixed with 0.1 mg/ml of sonicated herring sperm DNA in a hybridization buffer containing 100 mM 2-N-morpholino-ethane-sulfonic acid (MES), 1 M NaCl, 20 mM EDTA and 10% Tween 20 to make the hybridization mixture. The hybridization mixture containing the fragmented cRNA was denatured at 99°C for 5 min. and equilibrated for a further 5 min. at 45°C before centrifugation at 10,000 g for 5 min. to remove any insoluble material from the hybridization mixture. The hybridization mix was transferred to the ATH1-121501 genome array (Affymetrix, Santa Clara, CA, USA) cartridge and hybridized at 45°C for 16 h. on a rotisserie at 60 rpm.

After a 16 h. hybridization period the arrays were washed and stained in a Fluidics station (Affymetrix, Santa Clara, USA). The arrays were initially washed in a low stringency buffer A (6 × SSPE [0.9 M NaCl, 0.06 M NaH2PO4, 0.006 M EDTA], 10% Tween 20) at 25°C for 10 min. and then incubated with a high stringency buffer B (100 mM MES, 0.1 M NaCl, 10% Tween 20) at 50°C for 20 min. and stained with 10 mg/ml of streptavidin phycoerythrin (SAPE), in stain buffer containing 100 mM MES, 1 M NaCl, 0.05% Tween 20 and 2 mg/ml BSA at 25°C for 10 min. After a further wash in wash buffer A at 25°C for 20 min. they were stained with biotinylated anti-streptavidin antibody at 25°C for 10 min. After antibody staining the arrays were stained again with SAPE for signal amplification and washed with buffer A at 30°C for 30 min. The arrays were finally scanned and the intensities averaged with the Agilent GeneArray Scanner (Agilent Technology UK, West Lothian, UK).

Statistical analysis of Array data and Generation of Networks and Canonical Pathways

In order to identify genes of interest we used the S Score (Significance Score) algorithm as implemented in the Bioconductor software suite http://www.bioconductor.org[12] based on the R package http://www.r-project.org[13] that takes advantage of the fact that most genes are unchanged and calculates an S score (SD from the mean). The S score threshold of +/- 2.5 and an alpha value of P = 0.005 was used to define gene changes of interest. Data listing all genes that satisfied these criteria were analyzed by Ingenuity Pathway Analysis, Ingenuity® Systems, http://www.ingenuity.com. This generated functional networks and canonical pathways that connect the differentially expressed genes, using the IPA Knowledge base, where the interactions are supported by peer reviewed publications and which contains over 1.4 million interactions between genes, proteins, and drugs. Scores were assigned allowing ranking of the networks, using a Fisher's right tailed exact test.

Analysis of microarray data by real time quantitative PCR

To confirm microarray results, extracted HCA-7 total RNA was amplified by oligo dT(15) primers according to the Im-Prom II Kit (Promega UK, Southampton UK) methodology. Representative samples of genes from a number of the major functional groups and gene networks identified by IPA program were selected to confirm the array data using RQ-PCR analysis (Tables 1, 2 and 4) under appropriate conditions for an ABI Prism 7700. Primer and probe design utilized Primer Express software (Applied Biosystems, Warrington, UK). The primers were validated for gene specificity by agarose gel electrophoresis. Reporter dye-labelled probes were used with FAM (6-carboxyfluorescein) at the 5'-end and TAMRA (6-carboxy-tetramethyl-rhodamine) at the 3'-end. Reactions were set up in a final volume of 25 μl containing 12.5 μl of 2 × Taqman Universal PCR Mastermix (Applied Biosystems, Warrington, UK): 0.75 μl of each primer (10 pmol/μl), 0.5 μl of probe (10 pmol/μl), 2 μl of cDNA (equivalent to 5 ng total RNA/μl) and 8.5 μl of water. Samples were analyzed in triplicate and the emission released reporter dye was monitored by an ABI Prism 7700 Sequence Detector (Applied Biosystems, Warrington, UK) using the default PCR program of 2 min at 50°C and 10 min at 95°C; each cycle included denaturing at 95°C for 15 s and annealing at 60°C for 1 min. Analysis of the data was via the Sequence Detection System (SDS) software (Applied Biosystems, Warrington, UK). A no template control was included in each analysis and did not give any signal with any of the primer/probe combinations. RQ-PCR data were normalized using primers to β-actin based on the considerations outlined by Hugget et al. [14].
Table 1

Primers and probes used in the study

Gene

Forward Primer

Reverse Primer

Probe

β-actin

TCACCGAGCGCGGCT

TAATGTCACGCACGATTTCCC

CAGCTTCACCACCACGGCCGA

Interleukin-8

ATTTTCCTAGATATTGCACGGGAG

GCAAACCCATTCAATTCCTGA

AAAATTGAGGCCAAGGGCCAAGAGAA

ATPase, Na+/K+ transporting, Beta1 polypeptide

GCCCAGAGGGATGACATGAT

CAGACCTTTCGCTCTCCTCG

TTTGAAGATTGTGGCGATGTGCCCA

Syndecan 4

TGGGTGGTTGAGTGAGTGAATT

CCTCAACTATTCCAGCCCCAT

TTTCTCTTGCCCTGTTCCTGGTGCC

Retinoic acid receptor responder (tazarotene induced) 1

ACCCTGAGGAACCTGCTGGT

TGGTTTTTTGTTTCTCAGTCTGCT

TGAGCAGAGTTCAGTGTGCATGCGCT

tumor necrosis factor, alpha-induced protein 3

CTTTGAGTCAGGCTGTGGGC

TTGGATGCAATTCCTTCTTTCC

ACCACAGGGAGTAAATTGGCCTCTTTGATACA

nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha

GGCCTCCAAACACACAGTCA

GCTGCCAGAGAGTGAGGATGA

CTCCGTGAACTCTGACTCTGTGTCATAGCTCTC

matrix metallo-peptidase 7

GATCCCCCTGCATTTCAGG

CTGGCCCATCAAATGGGTAG

TCATGATTGGCTTTGCGCGAGG

Forward primer, reverse primer and Taqman probes for RQ-PCR assays used, all listed 5' - 3' direction.

Table 2

Up-regulated genes. Functional classes of genes shown are ordered by the S score of the most highly regulated examples in the class with S score ≥ 5.

Function

Symbol

Name

S Score

Chemokine

CCL20

Chemokine (C-C Motif) Ligand 20

13.542

 

CXCL3

Chemokine (C-X-C Motif) Ligand 3

11.866

 

CXCL2

Chemokine (C-X-C Motif) Ligand 2

11.742

 

IL8

Interleukin 8

11.393

 

CXCL1

Chemokine (C-X-C Motif) Ligand 1

11.096

 

CXCL6

Chemokine (C-X-C Motif) Ligand 6

10.79

 

CCL2

Chemokine (C-C Motif) Ligand 2

5.294

TNF/NFkB superfamily

TNFAIP3

Tumor Necrosis Factor, Alpha-Induced Protein 3

11.678

 

IKBA

Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha

10.956

 

TNIP1

TNFAIP3 Interacting Protein 1

9.344

 

TNFAIP2

Tumor Necrosis Factor, Alpha-Induced Protein 2

8.293

 

OPTN

Optineurin

6.487

 

IL32

Interleukin 32

6.12

 

NFKB1

Nuclear Factor Kappa B (P105)

5.355

Apoptosis/Cell death

UBD

Ubiquitin D

11.647

 

BIRC3

Baculoviral IAP Repeat-Containing 3

11.063

 

CFLAR

CASP8 And FADD-Like Apoptosis Regulator

6.224

 

SGK

Serum/Glucocorticoid Regulated Kinase

5.705

 

ISG20

Interferon Stimulated Exonuclease Gene 20 kda

5.575

Extracellular Matrix

MMP7

Matrix Metallopeptidase 7 (Matrilysin, Uterine)

9.812

 

SDC4

Syndecan 4 (Amphiglycan, Ryudocan)

8.923

 

LAMA3

Laminin, Alpha 3

5.824

 

LAMC2

Laminin, Gamma 2

5.32

Folate receptor

FOLR1

Folate Receptor 1 (Adult)

8.963

Redox state

SOD2

Superoxide Dismutase 2, Mitochondrial

8.879

 

TXNRD1

Thioredoxin Reductase 1

6.378

Cell adhesion

ICAM1

Intercellular Adhesion Molecule 1

8.879

 

FNDC3B

Fibronectin Type III Domain Containing 3B

5.851

Cytokines/Receptors

IFNGR1

Interferon Gamma Receptor 1

8.403

 

CSF2

Colony Stimulating Factor 2

5.101

 

PLAT

Plasminogen Activator, Tissue

7.464

 

SERPINB2

Serpin Peptidase Inhibitor 2

6.319

Energy metabolism

ATP1B1

Atpase, Na+/K+ Transporting, Beta 1 Peptide

7.184

Nuclear transcription

CEBPD

CCAAT/Enhancer Binding Protein Delta

6.708

 

RARRES1

Retinoic Acid Receptor Responder

6.179

Antibacterial

LCN2

Lipocalin 2

6.6

 

PI3

Peptidase Inhibitor 3 (Elafin)

5.057

Cell signalling

CDC42

Cell Division Cycle 42

7.28

 

DUSP5

Dual Specificity Phosphatase 5

6.541

 

SGPL1

Sphingosine-1-Phosphate Lyase 1

6.242

Cytoskeleton/cytokinesis

TPM1

Tropomyosin 1

5.689

 

PDLIM5

PDZ And LIM Domain 5

5.169

Transcription, protein synthesis and export

SF3B1

Splicing Factor 3b, Subunit 1,

5.146

 

UGCG

UDP-Glucose Ceramide Glucosyltransferase

5.388

Cell cycle

PLK2

Polo-Like Kinase 2

5.55

Structural

SYNGR3

Synaptogyrin 3

5.133

Antigen presentation

TAP1

Transporter 1, ATP-Binding Cassette

5.207

Chemokine and cytokine analyses

Cultured cells were prepared and induced as described above. After 6 h. incubation, the media was removed and stored at -20°C until examined using a Coulter-Alter Flow Cytometer in conjunction with a BD cytometric bead array human inflammation kit according to manufacturer's instructions (BD Biosciences, Oxford, UK). IL8 and CCL20 (MIP-3α) were specifically measured using a sandwich ELISA, by capture with a murine anti-human IL8 or CCL20 and detected using biotinylated goat anti-human IL8 using streptavidin-coupled horseradish-peroxidase, according to the manufacturer's instructions (R&D Systems, Minneapolis, MN, USA).

Results

The Bioconductor and IPA programs identified 356 genes that changed with a positive or negative S score of 2.5 or greater (maximum 13.54). Three hundred were up-regulated and 56 were down-regulated (Additional file 1).

Up-regulated genes

Table 2 shows 48 genes that were up-regulated with an S score of 5 or greater. These were grouped by class and ordered by the highest S score in each class. Chemokines dominate the most highly up-regulated genes with six of the ten highest S scores. Members of the TNFα-NF-κB super family were also highly up-regulated (Table 2). Other highly up-regulated genes were those involved in apoptosis and ubiquitination, extra-cellular matrix proteins, the folate receptor, superoxide dismutase, thioredoxin reductase, Intercellular Adhesion Molecule (ICAM) 1 and cytokines or their receptors (Colony Stimulating Factor [CSF] 2 and interferon-γ receptor 1).

Down-regulated genes

Fewer genes were down-regulated than those that were up-regulated and negative S scores were less pronounced than those for the up-regulated genes. For comparative purposes Table 3 shows down-regulated genes that were selected on the basis of a more permissive S score of -2.6 or less to yield a similar number (46). These genes were grouped by class and ordered by the highest negatively regulated (lowest value) S score in each class. The pattern of down-regulated gene classes differ markedly to those that were up-regulated. Most prominent were genes concerned with the maintenance of normal cell cycle, DNA replication and cell structure. The down-regulated group feature specific genes encoding components involved in membrane transport, mitosis, nucleotide synthesis, transcription, protein synthesis and export, membrane transport and energy metabolism.
Table 3

Down-regulated genes Functional classes of genes shown are ordered by the S score of the most highly regulated examples in the class with S score ≤ -2.6.

Function

Symbol

Name

S Score

Cell cycle, DNA replication and Mitosis

ID1

Inhibitor Of DNA Binding 1

-4.416

 

ID3

Inhibitor Of DNA Binding 3

-4.304

 

ID2

Inhibitor Of DNA Binding 2

-4.054

 

LHX3

LIM Homeobox 3

-3.181

 

KLF1

Kruppel-Like Factor 1

-2.97

 

FOXF2

Forkhead Box F2

-2.684

 

SFN

Stratifin

-4.086

 

FGFBP1

Fibroblast Growth Factor Binding Protein 1

-3.922

 

SKP2

S-Phase Kinase-Associated Protein 2 (P45)

-3.035

 

RPA3

Replication Protein A3

-2.975

 

RFC4

Replication Factor C 4

-2.845

 

SPBC25

Spindle Pole Body Component 25 Homolog

-2.688

Structural

REG1A

Regenerating Islet-Derived 1 Alpha

-4.213

 

CX36

Connexin-36

-3.79

 

COL4A5

Collagen, Type IV, Alpha 5

-3.69

 

ODF1

Outer Dense Fiber Of Sperm Tails 1

-3.511

 

CD248

CD248 Molecule, Endosialin

-2.965

Membrane transport

SLC2A1

Solute Carrier Family 2, Member 1

-3.912

 

CRIP1

Cysteine-Rich Protein 1 (Intestinal)

-3.079

 

SCNN1A

Sodium Channel, Nonvoltage-Gated 1 Alpha

-2.918

 

HFE

Hemochromatosis Gene

-2.723

Transcription, protein synthesis and export

CHMP6

Chromatin Modifying Protein 6

-3.599

 

RANBP1

RAN Binding Protein 1

-3.48

 

EHBP1

EH Domain Binding Protein 1

-3.106

 

RRM2

Ribonucleotide Reductase M2 Polypeptide

-2.957

 

CTDSPL

Small Carboxy-Terminal Domain Phosphatase

-2.838

 

DARS2

Aspartyl-Trna Synthetase 2 (Mitochondrial)

-2.795

 

POLR3K

Polymerase (RNA) Subunit K

-2.701

Nucleotide synthesis

UNG

Uracil-DNA Glycosylase

-3.553

 

GLRX

Glutaredoxin

-3.325

 

DUT

dUTP Pyrophosphatase

-2.967

 

TYMS

Thymidylate Synthetase

-2.687

Energy metabolism

ATAD4

ATPase Family, AAA Domain Containing 4

-3.185

 

COX7B

Cytochrome C Oxidase Subunit 7B

-2.893

Cytoskeleton/cytokinesis

M-RIP

Myosin Phosphatase-Rho Interacting Protein

-2.954

 

MALL

Mal, T-Cell Differentiation Protein-Like

-2.918

 

ARHGAP29

Rho Gtpase Activating Protein 29

-2.909

 

ROCK2

Rho-Associated, Coiled-Coil Containing Protein Kinase 2

-2.701

Cytokine

TGFB2

Transforming Growth Factor, Beta 2

-2.909

 

C1QTNF3

C1q And TNF Related Protein 3

2.701

Protease

SPINK1

Serine Peptidase Inhibitor, Kazal Type 1

-2.889

Cell adhesion

LGALS4

Galectin 4

-2.869

Redox

TXNIP

Thioredoxin Interacting Protein

-2.843

Cell signalling

HS1BP3

HS1-Binding Protein 3

-2.755

Anti-inflammatory

ANXA1

Annexin A1 (Lipocortin 1)

-2.703

Matrix

LAMB1

Laminin, Beta 1

-2.702

Signalling pathways

IPA identified a number of canonical signalling pathways that were most significantly affected (Figure 1). Figure 2 shows a simplified composite of all genes identified by IPA as being part of specific signalling pathways that are most significantly regulated, together with their individual S scores. Here the central mediator is the NF-κB signalling pathway that is clearly contributory in affecting the signalling through the Death Receptor, IL6, IL10, Toll-like receptor and PPAR pathways (also see Gene Networks section below and Figure 3 which also features NF-κB). In addition, several other canonical signalling pathways, some of which do not feature NF-κB, were also identified as significantly affected.
Figure 1

Canonical Signalling Pathways identified by IPA software as significantly regulated by C. jejuni BCE. A Fisher's exact test was used to calculate a p-value (Bars) determining the probability that the association between the genes in the dataset and the canonical pathway can be explained by chance alone. Threshold refers to the cut off for p < 0.05.

Figure 2

Regulated molecules in canonical signalling pathways identified by IPA. Individual pathways are identified by colours assigned in the black-backed heading at the top. Significantly up-regulated genes are shown in darker colour. Significantly down-regulated genes are shown stippled. Numerical values beside regulated genes show the S score. All genes identified by the IPA programme as significantly regulated have been included, together with a limited number of non-regulated genes to portray a simplified view of pathway continuity. For simplicity, molecules participating in more than one pathway are arbitrarily shown once in the most dominant pathway. Common transcriptional and other consequences of pathway activation are indicated in the Figure. Symbols are as in Figure See Figure 3 except that ---l = Inhibition (direct or indirect), ---ll = blocks translocation,) = Peptide, double helix = transcription.

Figure 3

IPA generated NF-κB-centred gene network. Network contains nodes (gene/gene product) and edges (indicating a relationship between the nodes) showing the cellular/subcellular location as indicated. An asterisk indicates that duplicates were identified in each dataset. Function classes of nodes indicated by shape to represent functional class, a plus sign indicates node is contained in other networks. All 35 focused genes are significantly up-regulated. Genes with an S score of ≥ 7 are shown in red and those with an S score of between 2.5–7 are shown pink. Explanation of edge types and shapes is indicated.

The antigen presentation pathway was identified through up-regulation of the Large Multifunctional Protease (LMP)-7, Transporter Associated with Antigen Processing (TAP) 1, TAP-binding protein (TAPBP), Calreticulin (CALR) and the Major Histocompatibility Complex (MHC)1-α.

Activation of the interferon-γ receptor defence signalling pathway was noted through up-regulation of both components of interferon-γ receptor, Janus kinase (JAK) 1 and Tyrosine Kinase (TYK) 2.

Activation of the ephrin signalling pathway, indicating activation of actin-based cytokinesis and repulsion. The pathway included up-regulation of ephrin receptor sub components, RHO family, GTP binding protein (Rac1), Cell Division Cycle (CDC) 42, Wiskott-Aldrich syndrome protein (WASP), actin-related protein 2 (ARP2), V-crk homologue (CRK) and Ras oncogene family member (RAP)1B with rho-associated coiled-coil containing protein kinase (ROCK) 2.

Finally, up-regulation of most components of the PI3K-phosphatase signalling pathway were noted, including phosphatase and tensin homology (PTEN) pathway indicating possible effects on the cell cycle, including Cell Division Cycle (CDC) 37, Forkhead Box (FOX)O1A and Cyclin Dependent Kinase Inhibitor (CDKN)1a (P21). SFN (Stratifin or 14-3-3σ) however, was down-regulated.

Predicted functional effects

The IPA program can determine if groups of significantly changed genes have related cellular and molecular functions (Figure 4). Here IPA identified 16 functional categories that were significantly affected by the C. jejuni BCE. The most prominent functions implicated were cellular movement (reflecting changes in chemokines, adhesion receptors and molecules affecting cytokinesis), cell growth and proliferation and cell death.
Figure 4

Functional Molecular and Cellular pathways significantly affected by C. jejuni BCE. A Fisher's exact test was used to calculate a p-value (Bars) determining the probability that the association between the genes in the dataset and the canonical pathway can be explained by chance alone. Threshold refers to the cut off for p < 0.05.

Gene networks

The IPA program constructed 16 interconnected gene networks that were significantly altered as a result of treatment of HCA-7 cells with C. jejuni BCE, all with network scores of ≥ 8. The network score is the probability that a network would be assembled by chance where a level of > 3 is statistically significant, at p < 0.001. In the four most significantly regulated all 35 focus genes of the network were affected, all giving an identical score of 52 (P < 1E-52).

The first network (Figure 3) contains genes concerned with cellular movement, particularly chemotaxis. NF-κB occupies a central position in the network and includes a number of genes which are known to up-regulate including a number of chemokines.

The second network (Additional file 2) likewise contains genes associated with cellular movement, including cytokinesis and inflammatory responses. Up-regulated genes include Ephrin Receptor B2 (EPHB2), PTGS2 (COX-2), ICAM1, both components of interferon-γ receptor, IL23A, IL27RA, JAK1, JUNB proto oncogene, Mitogen Activated Protein Kinase Kinase Kinase Kinase (MAP4K4), TYK2, Mothers Against DPP homologues (SMAD) 3, with 2 genes shown to be significantly down-regulated (SH2B and Transforming Growth Factor [TGF] β2).

MYC occupies a central position in the third network (Additional file 3), which contains genes concerned with the regulation of the cell cycle. Up-regulated genes include MYC as well as FAS, folate receptor (FOLR1), HLA molecules E, F and G, laminins β3, α3 (LAM-B3, A3) and γ2 (LAMC2), Matrix Metallo Proteinase (MMP)7, and SOD2. Down-regulated were Laminin β1 (LAMB1), RAN Binding Protein 1 (RANBP1) Thioredoxin Interacting Protein (TXNIP) and Thymidylate Synthetase (TYMS).

Finally, a network (Additional file 4) contains genes affecting cell death and gene expression. The network contains 25 genes that were up-regulated, including Activating Transcription Factor (ATF) 3, cellular Inhibitor of Apoptosis Proteins (cIAP) 1 and 2 (BIRC 2 and 3), cyclin dependent kinase (CDK) 7, cyclin dependant kinase inhibitor (CDKN) 1A, GATA binding protein (GATA) 6, TNFα-Induced Protein (TNFAIP) 2, the TNF-Related Apoptosis-Inducing Ligand (TRAIL or TNFSF10), its receptor TRAILR2 (TNFRSF10B or Death receptor [DR] 5) and TNF Receptor Associated Factor (TRAF) 2. Whilst CDKN1A is up-regulated, CDKN3 is down-regulated, as are the Inhibitors of DNA Binding (ID)1,2 and 3, Mini-Chromosome Maintenance homologue (MCM) 6, RCF4, rho-associated, coiled-coil containing protein kinase (ROCK) 2 and S-Phase Kinase-Associated Protein (SKP) 2.

Validation of Microarray data

Changes in gene expression identified by microarray were confirmed by RQ-PCR (Table 4). However, hierarchical differences are apparent between the RQ-PCR values normalized against β-actin compared with the S score associated with the significantly regulated genes as indicated by differential hybridization of the cRNA preparations to the microarray.
Table 4

Comparison of results for selected up-regulated genes determined by Affymetrix/S score and RQ-PCR.

Gene Description

Ingenuty Name

Affymetrix Probe Set

S Score

Fold RQ-PCR

Network

Location

Interleukin-8

IL8

211506_s_at

11.393

59.4 ± 15.5

See Figure 3

Extra-cellular

ATPase, Na+/K+ transporting, Beta 1 polypeptide

ATP1B1

201242_s_at

7.184

4.5 ± 1.8

10

Plasma Membrane

Syndecan 4

SDC4

202071_at

8.823

4.0 ± 0.84

5

Plasma Membrane

Retinoic acid receptor responder (tazarotene induced) 1

RARRES1

221872_at

6.179

2.4± 0.7

8

Plasma Membrane

tumor necrosis factor, alpha-induced protein 3

TNIP1

207196_s_at

9.344

2.0 ± 0.2

See Figure 3

Nucleus

nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha

NFKBIA

201502_s_at

10.956

4.0 ± 1.2.

See Figure 3

Cytoplasm

Matrix Metallo-peptidase 7

MMP7

202644_s_at

9.812

2.1 ± 4.2

9 & See Additional file 3

Extra-cellular

For each gene ingenuity description, name and Affymetrix probe set, assigned network and cellular location are shown together with the S score and fold RQ-PCR change compared to β-actin control.

Chemokine and cytokine responses

To further validate the gene transcriptional changes using microarray and RQ-PCR methods, we measured the levels of secretory immunomodulatory proteins in parallel cell supernatants of HCA-7 cells pre- and post-induction with C. jejuni BCE. Table 5 presents the chemokine and cytokine levels of pro- and anti-inflammatory secretory proteins. Consistent with the microarray observations the pro-inflammatory chemokine CCL20 showed a 12.6-fold increase in levels 6 h. post treatment. IL8 levels were also found to increase, but far more dramatically than CCL20 with a 460-fold induction. HCA-7 colonocytes are particularly IL8 responsive with post-induction levels of 18.4 ng/ml, an observation that is consistent with previous reports with this cell line [8]. The pro-inflammatory cytokine IL1β showed a weak response consistent with the transcriptional response recorded in the microarray study. Pro-inflammatory cytokine IL6 showed a 5-fold increase, whereas the anti-inflammatory cytokine IL10 remained static. The transcriptional response of the genes encoding IL6 and IL10 did not show marked transcriptional changes but the pathways associated with these immunomodulatory proteins were recognized by IPA and are responsive to NF-κB.
Table 5

Cytokine and chemokine levels (pg/ml) pre- and post-induction of HCA-7 cells with C. jejuni BCE for 6 h.

 

Pre-Induction

Post-Induction

Fold-Induction

IL10

12 (± 2)

15 (± 3)

1.25

IL6

30 (± 3)

150 (± 5)

5

IL1β

20 (± 4)

30 (± 6)

1.5

IL8

40 (± 16)

18,400 (± 400)

460

CCL20

30 (± 6)

380 (± 40)

12.6

Discussion

Understanding the pathogenesis of C. jejuni enteric disease is important both because C. jejuni is a major cause of diarrhoeal illness worldwide and because it may serve as a model for ulcerative colitis, the pathology of which it closely resembles [15]. Previous work has shown that direct interaction between C. jejuni and epithelial cells is capable of inducing pro-inflammatory and pro-secretory processes [8, 16]. These are associated with cellular invasion [17] and secretion of IL8 by CLDT dependent and independent mechanisms [16, 18]. Direct use of a BCE has allowed us to use a reductionist approach to investigate effects of C. jejuni that are not dominated by these linked processes of cellular invasion by live bacteria and by toxin based cell lysis. BCE has been determined to contain polysaccharide and protein components of the cell. As demonstrated previously the NF-κB inducing activity of C. jejuni BCE is relatively insensitive to digestion by protease K [8]. However the protein content has been determined using tryptic digests of SDS-polyacryamide extracted protein bands using MALDI-TOF mass spectrometry as flagellin (Cj1339c), trigger factor (Cj0193c), lipoprotein (Cj0983), major outer membrane protein (Cj0599), cytochrome-c peroxidase (Cj0358), bacterioferritin (Cj1534c), cell binding factor PEB4A (Cj0496), hypothetical protein (Cj0706), periplasmic protein (Cj0772c), fibronectin binding protein (Cj1478c), non-heme iron protein (Cj0012c), periplasmic protein (Cj1380), periplasmic protein (Cj0420), periplasmic protein (Cj0998c), DNA-binding protein HU (Cj0913c), periplasmic cytochrome C (Cj1153) and thioredoxin (Cj0147c) [11]. The polysaccharide component features α-glucan oligomers. The C. jejuni extract is notably devoid of the dominating heat-labile effects of the CLDT. C. jejuni BCE, like infection with live C. jejuni, has been shown to be a potent inducer of NF-κB using either luciferase based reporter assays, western blots with antibodies against IκB or electrophoretic mobility shift assays in epithelial cells [8] but, unlike treatment with live C. jejuni, this does not lead to host cell lysis. These observations are consistent with the hypothesis that a heat stable component plays a significant role in the pro-inflammatory response upon exposure to C. jejuni.

We hypothesize that NF-κB modulation is central to the response of enterocytes to C. jejuni BCE; to study this we determined the global changes in gene expression induced by C. jejuni BCE treatment of the well-differentiated human colonocyte line HCA-7, clone 29. In order to ensure the relevance of our results we have adopted stringent criteria for the identification of significantly affected genes and used the IPA program to determine the functional links between these gene products, identify the signalling pathways and networks to which they belong. These changes were validated by showing similar affects on mRNA levels when genes of interest were investigated by real-time quantitative PCR.

Consistent with the initial hypothesis that NF-κB plays a major role in the response of HCA-7 cells to C. jejuni BCE, and features in 8 of the 11 designated signalling pathways identified by IPA as up-regulated. Moreover, all genes in the NF-κB associated network (Figure 3) were up-regulated by C. jejuni BCE. The dominant component of this response concerned up regulation of chemokines that would act to induce the influx of acute inflammatory cells that characterize Campylobacter colitis. Our data are remarkably similar to transcriptomic data reported by Hinata et al., who activated NF-κB by transfecting clones expressing subunits of NF-κB to show up-regulation of the chemokines CXCL3 (GRO3) IL8, CXCL6, CXCL2 (GRO2), CXCL20 (SCYA20), CXCL1 (GRO1), CCL2 (CXYA2) as well as IL1α and CSF2, all of which were also significantly up-regulated in our study [19]. The NFKB1, NFKB2 and RELB components of NF-κB are also similarly up-regulated in our study. Other changes that are likely to be of functional importance and are the up-regulation of COX2 (PTGS2), TNIP2, MYC, SOD2, ELF3 and ICAM1 (Additional file 1), where all of these processes are also downstream targets of NF-κB [20] and mediators of feedback inhibition of NF-κB activation such as NFKBIA (IκB) [9], TNIP1 [21] and TNIP2 (Figure 3) [22]. A central role for NF-κB is also supported by data using the monocytic cell line THP-1 [23]. Studies in which Caco-2 cells were incubated with live bacteria resulted in expression of many genes similar to those reported here, including chemokines, but additionally, the NF-κB inhibitor NFKBIZ [24]. This difference may reflect the ability of live bacteria to invade cells and/or elaborate a CLDT with DNase activity [6].

The pattern of significantly down-regulated genes (Table 3) is remarkably different with a reduction in expression in constitutively expressed genes concerned with nucleotide synthesis, transcription, DNA replication, mitosis, structural protein synthesis, membrane transport and energy metabolism. These changes likely reflect the reprioritization of cellular metabolism in response to pro-inflammatory products.

Whether the changes caused by the C. jejuni BCE would lead to increased or reduced apoptosis is difficult to predict, especially as HCA-7 lack a functional TP53 protein, although these cells are capable of apoptosis given the appropriate signal [25]. Invasive C. jejuni infection can cause cell death in HCA-7 cells [16], although we did not see this with the addition of BCE [8]. Increased expression of members of the death receptor pathway, the TNFα superfamily and their receptors, but also of TNFα agonists may imply regulated activation of pro-apoptotic activity [2630]. Up-regulation of TRAIL, DR5, and FAS ligand acting via FADD, the universal adaptor protein known domain-containing members of the TNF receptor superfamily, would successively activate caspases 8, 10 and 3 as well as possible G1-S cell cycle progression [27]. However, the antagonists TNFAIP3, FLIP and cIAP, which respectively inhibit apoptosis via TRAF6, caspases 8, 9, 10 and TRAF-2 directly or indirectly are also prominent amongst the up-regulated genes [2932].

Moreover, several other key proteins for the cell cycle and apoptosis are affected. Thus CDKN1A (P21, WAF, WAF1 or CIP1) which plays a pivotal role in inhibiting cell cycle progression at several points in response to DNA damage [33], is up-regulated, as are FOXO1A and SMAD 2 (Additional file 1) and 3 (Additional file 2), which act together to increase CDKN1A activity [34, 35]. Conversely, other genes that inhibit cell cycle progression are down-regulated. These include SKP2, the F-box receptor that interacts with p19 and the CDK2/cyclin A to prevent entry into G1 [36] and SFN (stratifin or 14-3-3σ) a key target of the tumour suppressor gene TP53 which acts to cause G2 arrest [37].

Five other changes of potential functional importance are of note. Firstly, a number of potentially antibacterial agents are highly induced, including LCN2 (lipocalin-2) [38, 39] and PI3 (peptidase inhibitor 3, aka ELAFIN) [40], whilst MMP7 is thought to activate defensins [41]. Secondly, five key molecules involved in antigen processing and presentation (Figure 1, 2) [42] were also up-regulated and could play a role in the development of immune responses to C. jejuni. Thirdly, alterations in matrix metalloproteinases and leukocyte receptors would influence the inflammatory response, with MMP9 acting to facilitate neutrophil transfer by activating interleukin-8 [43] and MMP7 acting to localize them to sites of tissue damage [44]. Fourthly, the ephrin pathway (Figure 2), including Ephrin A2 and B2 receptors (EPHA2, EPHB2) and Ephrin A1 (EFNA1, Figure 3), rho kinase (ROCK2), Rac, ARP2/3, CDC42 and WASP appeared to be strongly up-regulated. This pathway is concerned with activation of cytokinetic changes that may potentially play a role in rapid restitution [45, 46]. Finally, up-regulation of the folate receptor (FOLR1) may reflect preparation for reparative nucleotide synthesis dependent upon one-carbon transfer activity [47].

Conclusion

The data we have generated using a BCE of C. jejuni represents a reductionist approach to determine some of the cellular responses associated with C. jejuni infection. However, because C. jejuni BCE represents a robust NF-κB inducing activity that is not only heat-stable but resistant to protease and acidic pH (pH 3) [8], these may indeed be of clinical significance if these products are shed upon C. jejuni infection or co-delivered through the diet. C. jejuni has been detected in many commercially available chicken portions [2] and clinical cases of Campylobacter enterocolitis are frequently associated with ingestion of partially cooked poultry meat [48].

Changes in host gene expression following C. jejuni BCE interestingly reflects some of the changes that are known to occur in inflammatory bowel diseases (IBD) such as ulcerative colitis, for which C. jejuni colitis can be considered a model, and may therefore indicate other potential targets for investigation of epithelial-derived mediators of inflammation in ulcerative colitis/IBD. Up-regulation of NF-κB is well recognized and considered a possible target of mesalazine [49, 50]. Genes up-regulated by C. jejuni that have been associated with active ulcerative colitis/IBD include chemokines [51], such as IL8 and CCL20 (macrophage inflammatory protein 3α) [5254] cytokines, including TNFα [55], eicosanoids [53] and elafin [56]. IL23, IL32 [5759] and receptors such as interferon-γ receptor, and TLR2 [60] have all been demonstrated to be altered here (Table 2, Additional file 1). Activation of pro-apoptotic pathways involving the TNF superfamily and death domain signalling pathway have been reported to be up-regulated in colonic enterocytes isolated from patients with ulcerative colitis, from which C-IAP2 (BIRC3) has been proposed as a disease marker [61], whilst the leukocytes serine anti-proteinase elafin has recently been identified as a candidate biomarker for ulcerative colitis but with attenuated induction in Crohn's disease [56]. Thus, the data we report here include a number of pathways and mediators that may be realistic anti-inflammatory therapeutic targets to prevent or reduce the activity of C. jejuni colitis or ulcerative colitis. These targets include mechanisms for chemoattraction of inflammatory cells, cellular processes associated with repair and the processes associated with apoptosis, as well as NF-κB itself, the utilization of which can be investigated by intervention studies in model systems and humans.

Declarations

Acknowledgements

We acknowledge the assistance if Drs. Janet Higgins and John Okyere, at NASC array service, University of Nottingham and Mr. Lyndon Cochrane for help with illustrations. IFC and KHM were the recipients of a grant award from the Biotechnology and Biological Research Council, UK

Authors’ Affiliations

(1)
Division of Food Sciences, School of Biosciences, University of Nottingham, Sutton Bonington Campus
(2)
MyCIB, School of Biosciences, University of Nottingham, Sutton Bonington Campus
(3)
Wolfson Digestive Diseases Centre, University Hospital Nottingham
(4)
Institute of Food Research, Norwich Research Park

References

  1. Snelling WJ, Matsuda M, Moore JE, Dooley JS: Campylobacter jejuni. Lett Appl Microbiol. 2005, 41 (4): 297-302. 10.1111/j.1472-765X.2005.01788.x.PubMedView ArticleGoogle Scholar
  2. Young KT, Davis LM, Dirita VJ: Campylobacter jejuni: molecular biology and pathogenesis. Nat Rev Microbiol. 2007, 5 (9): 665-679. 10.1038/nrmicro1718.PubMedView ArticleGoogle Scholar
  3. Jorgensen F, Bailey R, Williams S, Henderson P, Wareing DR, Bolton FJ, Frost JA, Ward L, Humphrey TJ: Prevalence and numbers of Salmonella and Campylobacter spp. on raw, whole chickens in relation to sampling methods. Int J Food Microbiol. 2002, 76 (1–2): 151-164. 10.1016/S0168-1605(02)00027-2.PubMedView ArticleGoogle Scholar
  4. Hughes RA, Cornblath DR: Guillain-Barre syndrome. Lancet. 2005, 366 (9497): 1653-1666. 10.1016/S0140-6736(05)67665-9.PubMedView ArticleGoogle Scholar
  5. Lecuit M, Abachin E, Martin A, Poyart C, Pochart P, Suarez F, Bengoufa D, Feuillard J, Lavergne A, Gordon JI, et al: Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med. 2004, 350 (3): 239-248. 10.1056/NEJMoa031887.PubMedView ArticleGoogle Scholar
  6. Guerry P: Campylobacter flagella: not just for motility. Trends Microbiol. 2007, 15 (10): 456-461. 10.1016/j.tim.2007.09.006.PubMedView ArticleGoogle Scholar
  7. Smith JL, Bayles DO: The contribution of cytolethal distending toxin to bacterial pathogenesis. Crit Rev Microbiol. 2006, 32 (4): 227-248. 10.1080/10408410601023557.PubMedView ArticleGoogle Scholar
  8. Mellits KH, Mullen J, Wand M, Armbruster G, Patel A, Connerton PL, Skelly M, Connerton IF: Activation of the transcription factor NF-kappaB by Campylobacter jejuni. Microbiology. 2002, 148 (Pt 9): 2753-2763.PubMedView ArticleGoogle Scholar
  9. Brasier AR: The NF-kappaB regulatory network. Cardiovasc Toxicol. 2006, 6 (2): 111-130. 10.1385/CT:6:2:111.PubMedView ArticleGoogle Scholar
  10. Kirkland SC: Dome formation by a human colonic adenocarcinoma cell line (HCA-7). Cancer Res. 1985, 45 (8): 3790-3795.PubMedGoogle Scholar
  11. Parkhill J, Wren BW, Mungall K, Ketley JM, Churcher C, Basham D, Chillingworth T, Davies RM, Feltwell T, Holroyd S, et al: The genome sequence of the food-borne pathogen Campylobacter jejuni reveals hypervariable sequences. Nature. 2000, 403 (6770): 665-668. 10.1038/35001088.PubMedView ArticleGoogle Scholar
  12. Kennedy RE, Kerns RT, Kong X, Archer KJ, Miles MF: SScore: an R package for detecting differential gene expression without gene expression summaries. Bioinformatics. 2006, 22 (10): 1272-1274. 10.1093/bioinformatics/btl108.PubMedView ArticleGoogle Scholar
  13. Zhang J, Carey V, Gentleman R: An extensible application for assembling annotation for genomic data. Bioinformatics. 2003, 19 (1): 155-156. 10.1093/bioinformatics/19.1.155.PubMedView ArticleGoogle Scholar
  14. Huggett J, Dheda K, Bustin S, Zumla A: Real-time RT-PCR normalisation; strategies and considerations. Genes Immun. 2005, 6 (4): 279-284. 10.1038/sj.gene.6364190.PubMedView ArticleGoogle Scholar
  15. Colgan T, Lambert JR, Newman A, Luk SC: Campylobacter jejuni enterocolitis. A clinicopathologic study. Arch Pathol Lab Med. 1980, 104 (11): 571-574.PubMedGoogle Scholar
  16. Beltinger J, Brough J, Skelly MM, Thornley J, Spiller RC, Stack WA, Hawkey CJ: Disruption of colonic barrier function and induction of mediator release by strains of Campylobacter jejuni that invade epithelial cells. 2008, 14 (48): 7345-52.Google Scholar
  17. Konkel ME, Kim BJ, Rivera-Amill V, Garvis SG: Identification of proteins required for the internalization of Campylobacter jejuni into cultured mammalian cells. Adv Exp Med Biol. 1999, 473: 215-224.PubMedView ArticleGoogle Scholar
  18. Hickey TE, McVeigh AL, Scott DA, Michielutti RE, Bixby A, Carroll SA, Bourgeois AL, Guerry P: Campylobacter jejuni cytolethal distending toxin mediates release of interleukin-8 from intestinal epithelial cells. Infect Immun. 2000, 68 (12): 6535-6541. 10.1128/IAI.68.12.6535-6541.2000.PubMed CentralPubMedView ArticleGoogle Scholar
  19. Hinata K, Gervin AM, Jennifer Zhang Y, Khavari PA: Divergent gene regulation and growth effects by NF-kappa B in epithelial and mesenchymal cells of human skin. Oncogene. 2003, 22 (13): 1955-1964. 10.1038/sj.onc.1206198.PubMedView ArticleGoogle Scholar
  20. Yamamoto Y, Gaynor RB: IkappaB kinases: key regulators of the NF-kappaB pathway. Trends Biochem Sci. 2004, 29 (2): 72-79. 10.1016/j.tibs.2003.12.003.PubMedView ArticleGoogle Scholar
  21. Heyninck K, Kreike MM, Beyaert R: Structure-function analysis of the A20-binding inhibitor of NF-kappa B activation, ABIN-1. FEBS Lett. 2003, 536 (1–3): 135-140. 10.1016/S0014-5793(03)00041-3.PubMedView ArticleGoogle Scholar
  22. Van Huffel S, Delaei F, Heyninck K, De Valck D, Beyaert R: Identification of a novel A20-binding inhibitor of nuclear factor-kappa B activation termed ABIN-2. J Biol Chem. 2001, 276 (32): 30216-30223. 10.1074/jbc.M100048200.PubMedView ArticleGoogle Scholar
  23. Jones MA, Totemeyer S, Maskell DJ, Bryant CE, Barrow PA: Induction of proinflammatory responses in the human monocytic cell line THP-1 by Campylobacter jejuni. Infect Immun. 2003, 71 (5): 2626-2633. 10.1128/IAI.71.5.2626-2633.2003.PubMed CentralPubMedView ArticleGoogle Scholar
  24. Rinella ES, Eversley CD, Carroll IM, Andrus JM, Threadgill DW, Threadgill DS: Human epithelial-specific response to pathogenic Campylobacter jejuni. FEMS Microbiol Lett. 2006, 262 (2): 236-243.PubMedView ArticleGoogle Scholar
  25. Huang X, Guo B: Adenomatous polyposis coli determines sensitivity to histone deacetylase inhibitor-induced apoptosis in colon cancer cells. Cancer Res. 2006, 66 (18): 9245-9251. 10.1158/0008-5472.CAN-06-0887.PubMedView ArticleGoogle Scholar
  26. Yan N, Shi Y: Mechanisms of apoptosis through structural biology. Annu Rev Cell Dev Biol. 2005, 21: 35-56. 10.1146/annurev.cellbio.21.012704.131040.PubMedView ArticleGoogle Scholar
  27. Werner MH, Wu C, Walsh CM: Emerging roles for the death adaptor FADD in death receptor avidity and cell cycle regulation. Cell Cycle. 2006, 5 (20): 2332-2338.PubMedView ArticleGoogle Scholar
  28. Wajant H, Scheurich P: Tumor necrosis factor receptor-associated factor (TRAF) 2 and its role in TNF signaling. Int J Biochem Cell Biol. 2001, 33 (1): 19-32. 10.1016/S1357-2725(00)00064-9.PubMedView ArticleGoogle Scholar
  29. Beyaert R, Heyninck K, Van Huffel S: A20 and A20-binding proteins as cellular inhibitors of nuclear factor-kappa B-dependent gene expression and apoptosis. Biochem Pharmacol. 2000, 60 (8): 1143-1151. 10.1016/S0006-2952(00)00404-4.PubMedView ArticleGoogle Scholar
  30. Liston P, Roy N, Tamai K, Lefebvre C, Baird S, Cherton-Horvat G, Farahani R, McLean M, Ikeda JE, MacKenzie A, et al: Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature. 1996, 379 (6563): 349-353. 10.1038/379349a0.PubMedView ArticleGoogle Scholar
  31. Kataoka T: The caspase-8 modulator c-FLIP. Crit Rev Immunol. 2005, 25 (1): 31-58. 10.1615/CritRevImmunol.v25.i1.30.PubMedView ArticleGoogle Scholar
  32. Li X, Yang Y, Ashwell JD: TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2. Nature. 2002, 416 (6878): 345-347. 10.1038/416345a.PubMedView ArticleGoogle Scholar
  33. Sherr CJ, Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999, 13 (12): 1501-1512. 10.1101/gad.13.12.1501.PubMedView ArticleGoogle Scholar
  34. Arden KC: FoxO: linking new signaling pathways. Mol Cell. 2004, 14 (4): 416-418. 10.1016/S1097-2765(04)00213-8.PubMedView ArticleGoogle Scholar
  35. Seoane J, Le HV, Shen L, Anderson SA, Massague J: Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell. 2004, 117 (2): 211-223. 10.1016/S0092-8674(04)00298-3.PubMedView ArticleGoogle Scholar
  36. Pagano M: Control of DNA synthesis and mitosis by the Skp2-p27-Cdk1/2 axis. Mol Cell. 2004, 14 (4): 414-416. 10.1016/S1097-2765(04)00268-0.PubMedView ArticleGoogle Scholar
  37. Wilker EW, van Vugt MA, Artim SA, Huang PH, Petersen CP, Reinhardt HC, Feng Y, Sharp PA, Sonenberg N, White FM, et al: 14-3-3sigma controls mitotic translation to facilitate cytokinesis. Nature. 2007, 446 (7133): 329-332. 10.1038/nature05584.PubMedView ArticleGoogle Scholar
  38. Flo TH, Smith KD, Sato S, Rodriguez DJ, Holmes MA, Strong RK, Akira S, Aderem A: Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature. 2004, 432 (7019): 917-921. 10.1038/nature03104.PubMedView ArticleGoogle Scholar
  39. Borregaard N, Cowland JB: Neutrophil gelatinase-associated lipocalin, a siderophore-binding eukaryotic protein. Biometals. 2006, 19 (2): 211-215. 10.1007/s10534-005-3251-7.PubMedView ArticleGoogle Scholar
  40. Sallenave JM: The role of secretory leukocyte proteinase inhibitor and elafin (elastase-specific inhibitor/skin-derived antileukoprotease) as alarm antiproteinases in inflammatory lung disease. Respir Res. 2000, 1 (2): 87-92. 10.1186/rr18.PubMed CentralPubMedView ArticleGoogle Scholar
  41. Wilson CL, Ouellette AJ, Satchell DP, Ayabe T, Lopez-Boado YS, Stratman JL, Hultgren SJ, Matrisian LM, Parks WC: Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense. Science. 1999, 286 (5437): 113-117. 10.1126/science.286.5437.113.PubMedView ArticleGoogle Scholar
  42. Kloetzel PM: Generation of major histocompatibility complex class I antigens: functional interplay between proteasomes and TPPII. Nat Immunol. 2004, 5 (7): 661-669. 10.1038/ni1090.PubMedView ArticleGoogle Scholar
  43. Steen Van den PE, Proost P, Wuyts A, Van Damme J, Opdenakker G: Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood. 2000, 96 (8): 2673-2681.PubMedGoogle Scholar
  44. Li Q, Park PW, Wilson CL, Parks WC: Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell. 2002, 111 (5): 635-646. 10.1016/S0092-8674(02)01079-6.PubMedView ArticleGoogle Scholar
  45. Kullander K, Klein R: Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol. 2002, 3 (7): 475-486. 10.1038/nrm856.PubMedView ArticleGoogle Scholar
  46. Anton IM, Jones GE, Wandosell F, Geha R, Ramesh N: WASP-interacting protein (WIP): working in polymerisation and much more. Trends Cell Biol. 2007, 17 (11): 555-562. 10.1016/j.tcb.2007.08.005.PubMedView ArticleGoogle Scholar
  47. Stanger O: Physiology of folic acid in health and disease. Curr Drug Metab. 2002, 3 (2): 211-223. 10.2174/1389200024605163.PubMedView ArticleGoogle Scholar
  48. Friedman CR, Neimann J, Wegener HC, Tauxe RV: Epidemiology of Campylobacter jejuni infections in the United States and other industrialized nations. Campylobacter. Edited by: Nachamkin I, Blaser MJ. 2000, Washington, DC ASM Press, 121-138. 2Google Scholar
  49. Zhang SZ, Zhao XH, Zhang DC: Cellular and molecular immunopathogenesis of ulcerative colitis. Cell Mol Immunol. 2006, 3 (1): 35-40.PubMedGoogle Scholar
  50. Bantel H, Berg C, Vieth M, Stolte M, Kruis W, Schulze-Osthoff K: Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol. 2000, 95 (12): 3452-3457.PubMedGoogle Scholar
  51. Papadakis KA: Chemokines in inflammatory bowel disease. Curr Allergy Asthma Rep. 2004, 4 (1): 83-89. 10.1007/s11882-004-0048-7.PubMedView ArticleGoogle Scholar
  52. Mahida YR, Ceska M, Effenberger F, Kurlak L, Lindley I, Hawkey CJ: Enhanced synthesis of neutrophil-activating peptide-I/interleukin-8 in active ulcerative colitis. Clinical Science. 1992, 82 (3): 273-275.PubMedView ArticleGoogle Scholar
  53. Cole AT, Pilkington BJ, McLaughlan J, Smith C, Balsitis M, Hawkey CJ: Mucosal factors inducing neutrophil movement in ulcerative colitis: the role of interleukin 8 and leukotriene B4. Gut. 1996, 39 (2): 248-254. 10.1136/gut.39.2.248.PubMed CentralPubMedView ArticleGoogle Scholar
  54. Watanabe S, Yamakawa M, Hiroaki T, Kawata S, Kimura O: Correlation of dendritic cell infiltration with active crypt inflammation in ulcerative colitis. Clin Immunol. 2007, 122 (3): 288-297. 10.1016/j.clim.2006.10.013.PubMedView ArticleGoogle Scholar
  55. Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, Bamba T, Fujiyama Y: Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003, 52 (1): 65-70. 10.1136/gut.52.1.65.PubMed CentralPubMedView ArticleGoogle Scholar
  56. Flach CF, Eriksson A, Jennische E, Lange S, Gunnerek C, Lonnroth I: Detection of elafin as a candidate biomarker for ulcerative colitis by whole-genome microarray screening. Inflamm Bowel Dis. 2006, 12 (9): 837-842. 10.1097/01.mib.0000232469.23574.11.PubMedView ArticleGoogle Scholar
  57. McGovern D, Powrie F: The IL23 axis plays a key role in the pathogenesis of IBD. Gut. 2007, 56 (10): 1333-1336. 10.1136/gut.2006.115402.PubMed CentralPubMedView ArticleGoogle Scholar
  58. Lakatos PL, Szamosi T, Szilvasi A, Molnar E, Lakatos L, Kovacs A, Molnar T, Altorjay I, Papp M, Tulassay Z, et al: ATG16L1 and IL23 receptor (IL23R) genes are associated with disease susceptibility in Hungarian CD patients. 2008, 40 (11): 867-73.Google Scholar
  59. Shioya M, Nishida A, Yagi Y, Ogawa A, Tsujikawa T, Kim-Mitsuyama S, Takayanagi A, Shimizu N, Fujiyama Y, Andoh A: Epithelial overexpression of interleukin-32alpha in inflammatory bowel disease. Clin Exp Immunol. 2007, 149 (3): 480-486.PubMed CentralPubMedView ArticleGoogle Scholar
  60. Rodriguez-Bores L, Fonseca GC, Villeda MA, Yamamoto-Furusho JK: Novel genetic markers in inflammatory bowel disease. World J Gastroenterol. 2007, 13 (42): 5560-5570.PubMed CentralPubMedView ArticleGoogle Scholar
  61. Seidelin JB, Nielsen OH: Expression profiling of apoptosis-related genes in enterocytes isolated from patients with ulcerative colitis. Apmis. 2006, 114 (7–8): 508-517. 10.1111/j.1600-0463.2006.apm_116.x.PubMedView ArticleGoogle Scholar

Copyright

© Mellits et al; licensee BioMed Central Ltd. 2009

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement